Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
View original at finance.yahoo.comLilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clea…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Children with moderate-to-severe atopic dermatitis often endure relentless skin flares, itch and discomfort that can disrupt play, school and daily life for patients and caregivers
60% confidenceLilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans
60% confidenceIL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection
60% confidenceAdditional results from ADorable-1 and ADorable-2 will be disclosed later this year
60% confidenceEBGLYSS is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
60% confidenceThe topline results from ADorable-1 offer hope for young patients, delivering near-complete skin clearance and significant itch relief with a highly selective medicine that targets the underlying inflammation
60% confidenceThe safety of EBGLYSS was consistent with the known profile in adult and adolescent patients, with no new safety signals observed in ADorable-1
60% confidenceEBGLYSS has already changed what's possible for adults and adolescents, delivering durable results that help patients flare less with the option of monthly maintenance dosing
60% confidenceLilly plans to submit ADorable-1 data to U.S. and global regulators for a potential label update
60% confidenceInfants and young children with moderate-to-severe atopic dermatitis have fewer approved treatment options than adults and adolescents
60% confidenceAtopic dermatitis affects 9.6 million children in the U.S., one-third of whom have moderate-to-severe disease
60% confidence
Data points we hold from this source
| Eli Lilly and Company · commercial insurance coverage | 94 percent |